Friday, December 2, 2022

Brent Warner Appointed Poseida Therapeutics President Gene Therapy

Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022.

“Brent Warner brings deep pharmaceutical expertise and a strong track record of leadership in gene therapy and rare genetic diseases to Poseida, and I am excited to welcome him to our team,” said Mark Gergen, Chief Executive Officer of Poseida. “Alongside our top scientists, he will lead the execution of drug development programs in gene therapy, including our recent research collaboration with Takeda. It’s an exciting time at Poseida, and I look forward to working with Brent as we continue to advance our innovative gene therapy programs.”

Brent Warner has more than 15 years of biotech and pharmaceutical experience, most recently serving as Vice President, Gene Therapy and Rare Disease at Novartis, where he was responsible for building a division to commercialize multiple gene therapies overseeing three therapeutic areas. Prior roles included serving as a U.S. commercial leader in Hemophilia A at BioMarin Pharmaceutical Inc. and a variety of strategic operational roles at Biogen. Before that, he held commercial launch roles in blood disorders at Baxalta, then a biopharmaceutical division spun off by Baxter International and now a wholly owned subsidiary of Takeda. Warner has an MBA with an emphasis in marketing and finance and a Bachelor of Business Administration degree, both from Northwood University in Midland, Mich.

“I am thrilled to join Poseida, which has built an unparalleled platform to deliver novel cell and gene therapies for patients with high unmet need,” Warner said.  “Together with Poseida’s outstanding team, I look forward to the opportunity to accelerate potential single-treatment cures for the rare disease community.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy